Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.

Sorenmo KU, Baez JL, Clifford CA, Mauldin E, Overley B, Skorupski K, Bachman R, Samluk M, Shofer F.

J Vet Intern Med. 2004 Mar-Apr;18(2):209-13.

2.

Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Kahn SA, Mullin CM, de Lorimier LP, Burgess KE, Risbon RE, Fred RM 3rd, Drobatz K, Clifford CA.

Can Vet J. 2013 Mar;54(3):237-42.

3.

Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.

Finotello R, Stefanello D, Zini E, Marconato L.

Vet Comp Oncol. 2017 Mar;15(1):25-35. doi: 10.1111/vco.12139. Epub 2015 Jan 26.

PMID:
25623994
4.

Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide.

Sorenmo KU, Jeglum KA, Helfand SC.

J Vet Intern Med. 1993 Nov-Dec;7(6):370-6.

5.

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S.

J Vet Intern Med. 2007 Jul-Aug;21(4):764-9.

6.

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD.

BMC Vet Res. 2015 Jun 11;11:131. doi: 10.1186/s12917-015-0446-1.

7.

Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.

Sorenmo K, Samluk M, Clifford C, Baez J, Barrett JS, Poppenga R, Overley B, Skorupski K, Oberthaler K, Van Winkle T, Seiler G, Shofer F.

J Vet Intern Med. 2007 Nov-Dec;21(6):1347-54.

8.

Canine hemangiosarcoma treated with standard chemotherapy and minocycline.

Sorenmo K, Duda L, Barber L, Cronin K, Sammarco C, Usborne A, Goldschmidt M, Shofer F.

J Vet Intern Med. 2000 Jul-Aug;14(4):395-8.

9.

Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).

Bulakowski EJ, Philibert JC, Siegel S, Clifford CA, Risbon R, Zivin K, Cronin KL.

J Am Vet Med Assoc. 2008 Jul 1;233(1):122-8. doi: 10.2460/javma.233.1.122.

PMID:
18593321
10.

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.

U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW.

J Vet Intern Med. 2007 Jan-Feb;21(1):113-20.

11.

Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma.

Wiley JL, Rook KA, Clifford CA, Gregor TP, Sorenmo KU.

Vet Comp Oncol. 2010 Sep;8(3):221-33. doi: 10.1111/j.1476-5829.2010.00221.x.

PMID:
20691029
12.

Surgery and doxorubicin in dogs with hemangiosarcoma.

Ogilvie GK, Powers BE, Mallinckrodt CH, Withrow SJ.

J Vet Intern Med. 1996 Nov-Dec;10(6):379-84.

13.

Treatment with DAV for advanced-stage hemangiosarcoma in dogs.

Dervisis NG, Dominguez PA, Newman RG, Cadile CD, Kitchell BE.

J Am Anim Hosp Assoc. 2011 May-Jun;47(3):170-8. doi: 10.5326/JAAHA-MS-5525. Epub 2011 Apr 15.

PMID:
21498593
14.

VAC protocol for treatment of dogs with stage III hemangiosarcoma.

Alvarez FJ, Hosoya K, Lara-Garcia A, Kisseberth W, Couto G.

J Am Anim Hosp Assoc. 2013 Nov-Dec;49(6):370-7. doi: 10.5326/JAAHA-MS-5954. Epub 2013 Sep 19.

PMID:
24051260
15.

Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).

Kim SE, Liptak JM, Gall TT, Monteith GJ, Woods JP.

J Am Vet Med Assoc. 2007 Nov 15;231(10):1550-7.

PMID:
18021000
16.

Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma.

Higginbotham ML, McCaw DL, Roush JK, Nietfeld JC, Wilkerson MJ, Reeds K, Burr D.

J Am Anim Hosp Assoc. 2013 Nov-Dec;49(6):357-62. doi: 10.5326/JAAHA-MS-5929. Epub 2013 Sep 19.

PMID:
24051255
17.

Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.

Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S, Jurina K, Scharvogel S, Schwedes C, Reinacher M, Beyerbach M, Nolte I.

J Am Vet Med Assoc. 2008 Mar 15;232(6):879-85. doi: 10.2460/javma.232.6.879.

PMID:
18341445
18.
19.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Oct;1(10):1165-70.

Supplemental Content

Support Center